CN107828663A - A kind of indoles diterpene-kind compound crystal and its application as antineoplastic - Google Patents

A kind of indoles diterpene-kind compound crystal and its application as antineoplastic Download PDF

Info

Publication number
CN107828663A
CN107828663A CN201710416276.1A CN201710416276A CN107828663A CN 107828663 A CN107828663 A CN 107828663A CN 201710416276 A CN201710416276 A CN 201710416276A CN 107828663 A CN107828663 A CN 107828663A
Authority
CN
China
Prior art keywords
compound
crystal
antineoplastic
diterpene
indoles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201710416276.1A
Other languages
Chinese (zh)
Other versions
CN107828663B (en
Inventor
郑彩娟
黄国雷
白猛
陈光英
罗由萍
周学明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hainan Normal University
Original Assignee
Hainan Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hainan Normal University filed Critical Hainan Normal University
Priority to CN201710416276.1A priority Critical patent/CN107828663B/en
Publication of CN107828663A publication Critical patent/CN107828663A/en
Application granted granted Critical
Publication of CN107828663B publication Critical patent/CN107828663B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/145—Fungal isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

The X ray single crystal diffraction data of a kind of application the present invention relates to indoles diterpene-kind compound crystal and its as antineoplastic, wherein indoles diterpene-kind compound crystal are：Orthorhombic system, space group P212121, cell parameter isα=90 °, β=90 °, γ=90 °,Z=4, Dx=1.142mg/mm3, F (000)=928, μ (Cu K α)=0.540mm‑1, final discrepancy factor R1=0.05046, wR2=0.1067 [I>2 σ (I)], Flack constants are 0.0 (2).

Description

A kind of indoles diterpene-kind compound crystal and its application as antineoplastic
Technical field
The invention belongs to marine drug field, and in particular to a kind of indoles diterpene-kind compound crystal and its conduct are antitumor The application of medicine.
Background technology
Mangrove is grown on tropical and subtropical zone intertidal zone, and its living environment has the characteristics that high pressure, high salt, hypoxemia, makes Obtaining its endogenetic fungus has unique metabolic pathway, and then with the energy for producing structure novelty, the compound of diverse biological activities Power, its metabolite have a variety of medical values such as antibacterial, antitumor, immunological regulation, enzyme level, are potential microbial medicines Exploit natural resources, therefore, mangrove endogeny eumycete is by one of valuable source as new drug development.
Using the method for artificial cultivation and fermentation, the secondary generation of important antibacterial activity is obtained from mangrove endogeny eumycete Thank to product, there is environment-friendly, sustainable development, can effectively solve that the medicine source in drug discovery process etc. is key to ask Topic, therefore there is unique advantage.
The content of the invention
The present invention provides a kind of marine fungi Eupenicillium sp.HJ002, and the fungi is isolated from xylocarpus granatum, wherein Xylocarpus granatum is that inventor is gathered from Hainan Dong Zhaigang Mangrove Nature Reserves in September, 2015.Marine fungi of the present invention Eupenicillium sp.HJ002 culture presevation information：Depositary institution's title：Chinese microorganism strain preservation conservator Can common micro-organisms center；Depositary institution address：Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3, Chinese Academy of Sciences microorganism are ground Study carefully institute；Preservation date：On December 21st, 2016；Deposit number：CGMCC No.13373；Classification And Nomenclature：Penicillium Eupenicillium sp.。
The present invention provide a kind of mangrove xylocarpus granatum originated from fungus indoles diterpene-kind compound or its can pharmaceutically connect The salt received, it is characterised in that the indoles diterpene-kind compound has the structure shown in following compound 1-3：
The present invention provides a kind of method for preparing above-mentioned indoles diterpene-kind compound 1-3, it is characterised in that including following step Suddenly：
(1) seed culture medium is prepared, marine fungi Eupenicillium sp.HJ002 bacterial strains are accessed into seed culture medium, 26~28 DEG C, culture obtains seed culture fluid in 3~4 days；
(2) in the seed culture fluid access fermentation medium obtained step (1), 26~28 DEG C of quiescent cultures 21~28 days Obtain fermentate；
(3) zymotic fluid in the fermentate for obtaining step (2) and thalline separation, the isometric ethyl acetate of zymotic fluid Extract 2~4 times, medicinal extract is concentrated under reduced pressure to give after combined ethyl acetate phase；
(4) medicinal extract that step (3) obtains is by decompression silica gel column chromatography, using petroleum ether-ethyl acetate as eluant, eluent Gradient elution is carried out, gradient is respectively 100:0、90:10、80:20、70:30、60:40,50:50、40:60、30:70、 20:80、10:90、0:100, each gradient collects two column volumes, is divided into 6 components, wherein gradient 100 according to polarity size: 0~90:10 afford for component 1, gradient 80:20~70:30 afford for component 2, gradient 60:40~50:50 Afford for component 3, gradient 40:60~30:70 afford for component 4, gradient 20:80~10:90 afford For component 5, gradient 0:100 afford for component 6, wherein for component 4 first through normal-phase silica gel column chromatography, eluant, eluent is oil Ether：Ethyl acetate=5:1-2:1 mixed solvent, 2-5 column volume is eluted, is coagulated again through Sephadex LH-20 after being concentrated under reduced pressure Plastic column chromatography, eluant, eluent CHCl3:MeOH=1:1 mixed solvent, 3-6 column volume is eluted, again through efficient after being concentrated under reduced pressure Prepared by liquid chromatogram HPLC, chromatographic column is Waters C18,9.4 × 250mm, 7 μm, flow velocity 2mL/min, and mobile phase is MeOH:H2O=80:30-75:25, compound 3 and compound 2 are obtained successively；Component 5 is first through Sephadex LH-20 gel columns Chromatography, eluant, eluent MeOH, 3-6 column volume is eluted, is prepared again through high-efficient liquid phase chromatogram HPLC after being concentrated under reduced pressure, chromatographic column is Waters C18,9.4 × 250mm, 7 μm, flow velocity 2mL/min, mobile phase MeOH:H2O=72:28, obtain compound 1.
The ratio of wherein described eluant, eluent or mobile phase is volume ratio；Contain glucose in the seed culture medium 1.5% -3.0%, yeast extract 0.1% -0.5%, peptone 0.1% -0.5%, coarse sea salt 0.11% -0.6%, appropriate water； Contain glucose 1.6% -3.5%, yeast extract 0.1% -0.5%, peptone 0.1% -0.5%, thick in the fermentation medium Sea salt 0.11% -0.6%, appropriate water；Above-mentioned percentage is weight percentage；The seed culture medium and fermentation medium 120 DEG C are both needed to go out 25-30 minutes.
Another embodiment of the present invention provides the crystal of compound 1, it is characterised in that its X-ray single crystal diffraction data For：Orthorhombic system, space group P212121, cell parameter is α=90 °, β=90 °, γ=90 °,Z=4, Dx=1.142mg/mm3, F (000)=928, μ (Cu K α)=0.540mm-1, final discrepancy factor R1=0.05046, wR2=0.1067 [I>2 σ (I)], Flack constants are 0.0 (2).
Another embodiment of the present invention provides the crystal of compound 2, it is characterised in that its X-ray single crystal diffraction data is： Orthorhombic system, space group P212121, cell parameter is α =90 °, β=90 °, γ=90 °,Z=4, Dx=1.155mg/mm3, F (000)=920, μ (Cu K α) =0.548mm-1, final discrepancy factor R1=0.0323, wR2=0.0746 [I>2 σ (I)], Flack constants are -0.01 (17).
The present invention provides the preparation method of the crystal of compound 1 or 2, it is characterised in that compound 1 or 2 is dissolved in solvent, Spontaneous nucleation obtains, and the solvent is the one or more in methanol, ethanol, dichloromethane, petroleum ether or ethyl acetate.
The present invention provides a kind of antineoplastic, it is characterised in that with above-mentioned indoles diterpene-kind compound 1-3, its crystal or Its pharmaceutically acceptable salt is as active ingredient.
Above-mentioned antineoplastic provided by the invention, also comprising other antineoplastics；Can also include can pharmaceutically connect The carrier or excipient received.
Another embodiment of the present invention provide described indoles diterpene-kind compound 1-3, its crystal or its pharmaceutically may be used Purposes of the salt of receiving in antineoplastic is prepared.Described tumour preferred A549, Hela, HepG2.
Term " pharmaceutically acceptable salt " refers to the addition of atoxic inorganic or organic acid and/or alkali in the present invention Salt, reference can be made to " Salt selection for basic drugs ", Int.J.Pharm. (1986), 33,201-217.
Brief description of the drawings
The XRD of Fig. 1 compounds 1.
The XRD of Fig. 2 compounds 2.
Embodiment
For the ease of a further understanding of the present invention, examples provided below has done more detailed description to it.But It is that these embodiments only are not used for limiting the scope of the present invention or implementation principle, reality of the invention for being better understood from inventing The mode of applying is not limited to herein below.
Embodiment 1
(1) marine fungi Eupenicillium sp.HJ002 Spawn incubation
Prepare seed culture medium：Glucose 80g, peptone 8g, yeast extract 8g, coarse sea salt 10g, water 4.0L, average packing In 8 1000mL conical flasks, 120 DEG C go out 25-30 minutes.
In the seed culture medium that the access of fungi Eupenicillium sp.HJ002 bacterial strains is prepared, in 26~28 DEG C Under, culture obtains seed culture fluid in 3 days；
(2) marine fungi Eupenicillium sp.HJ002 fermentation
Prepare fermentation medium：Glucose 1.1kg, peptone 100g, yeast extract 100g, sea salt 125g, water 50L are average It is sub-packed in 75 1000mL conical flasks, 120 DEG C go out 25-30 minutes.
The seed culture fluid that is obtained in appropriate step (1) is taken to access in the conical flask equipped with fermentation medium, in 26~ 28 DEG C of quiescent cultures 21 days.
(3) compound 1-3 extraction separation
Take the fermentate filtering that 15L steps (2) obtain, separation and fermentation liquid and thalline, the isometric acetic acid second of zymotic fluid Ester extracts 2-3 times；Be concentrated under reduced pressure to obtain medicinal extract after combined ethyl acetate phase, medicinal extract by decompression silica gel column chromatography, using petroleum ether- Ethyl acetate carries out gradient elution as eluant, eluent, and gradient is respectively 100:0、90:10、80:20、70:30、60:40, 50:50、40:60、30:70、20:80、10:90、0:100, each gradient collects two column volumes, is divided into 6 according to polarity size Individual component, wherein gradient 100:0~90:10 afford for component 1, gradient 80:20~70:30 afford for component 2, gradient 60:40~50:50 afford for component 3, gradient 40:60~30:70 afford for component 4, gradient 20: 80~10:90 afford for component 5, gradient 0:100 afford for component 6, wherein component 4 is first through normal phase silicagel column Chromatography, eluant, eluent is petroleum ether：Ethyl acetate=5:1-2:1 mixed solvent, 2-5 column volume is eluted, after being concentrated under reduced pressure again Through Sephadex LH-20 gel filtration chromatographies, eluant, eluent CHCl3:MeOH=1:1 mixed solvent, 3-6 column volume is eluted, Prepared again through high-efficient liquid phase chromatogram HPLC after being concentrated under reduced pressure, chromatographic column is Waters C18,9.4 × 250mm, 7 μm, and flow velocity is 2mL/min, mobile phase MeOH:H2O=80:30-75:25, compound 3 (1.5mg) and compound 2 (6.4mg) are obtained successively； Component 5 first through Sephadex LH-20 gel filtration chromatographies, eluant, eluent MeOH, elutes 3-6 column volume, passed through again after being concentrated under reduced pressure Prepared by high-efficient liquid phase chromatogram HPLC, chromatographic column is Waters C18,9.4 × 250mm, 7 μm, flow velocity 2mL/min, and mobile phase is MeOH:H2O=72:28, obtain compound 1 (7.2mg).
Compound 1-3 structural identification data is as follows：
The compound 1-3's of table 11H(400MHz)and 13C (100MHz) NMR data (MeOD)
Compound 1：IR(KBr)νmax 3427,1636,1455,1377,1243,1121,731cm–1；1H and13C NMR It is shown in Table 1；HRESIMS m/z 424.3204[M+H]+(calcd for C28H42NO2,424.3210)。
Compound 2：λmax(logε)226(4.02),276(3.50),294(3.34)nm；IR(KBr)νmax 3420, 1710,1602,1432,1366,1230,1110,738cm–1；1H and 13C NMR are shown in Table 1；HRESIMS m/z 422.3048 [M+H]+(calcd for C28H40NO2,422.3054)。
Compound 3：IR(KBr)νmax 3518,1712,1602,1272,1250,1230,1112,1082,1064, 798cm–1；1H and 13C NMR are shown in Table 1；HRESIMS m/z 422.3050[M+H]+(calcd for C28H40NO2, 422.3054)。
Embodiment 2
(1) fungi Eupenicillium sp.HJ002 Spawn incubation
Prepare seed culture medium (5.0L)：Glucose 1.5% (percentage by weight, similarly hereinafter), yeast extract 0.5%, peptone 0.1%th, coarse sea salt 0.11%, remaining is water；Average mark is loaded on 8 1000mL conical flasks, and 120 DEG C go out 25-30 minutes.
In the seed culture medium that the access of fungi Eupenicillium sp.HJ002 bacterial strains is prepared, in 26~28 DEG C Under, culture obtains seed culture fluid in 4 days；
(2) fungi Eupenicillium sp.HJ002 fermentation
Prepare fermentation medium (100L)：Glucose 1.6% (percentage by weight, similarly hereinafter), yeast extract 0.5%, peptone 0.1%th, coarse sea salt 0.11%, remaining is water；Average mark is loaded on 150 1000mL conical flasks, and 120 DEG C go out 25-30 minutes.
The seed culture fluid that is obtained in appropriate step (1) is taken to access in the conical flask equipped with fermentation medium, in 26~ 28 DEG C of quiescent cultures 28 days.
(3) compound 1-3 extraction separation
According to separation method similar in embodiment 1, compound 1-3, structural identification data and embodiment 1 one can obtain Cause.
Embodiment 3
(1) fungi Eupenicillium sp.HJ002 Spawn incubation
Prepare seed culture medium (1.0L)：Glucose 3.0% (percentage by weight, similarly hereinafter), yeast extract 0.1%, peptone 0.5%th, coarse sea salt 0.6%, remaining is water；Average mark is loaded on 3 500mL conical flasks, and 120 DEG C go out 25-30 minutes.
In the seed culture medium that the access of fungi Eupenicillium sp.HJ002 bacterial strains is prepared, in 26~28 DEG C Under, culture obtains seed culture fluid in 4 days；
(2) fungi Eupenicillium sp.HJ002 fermentation
Prepare fermentation medium (20L)：Glucose 3.5% (percentage by weight, similarly hereinafter), yeast extract 0.1%, peptone 0.5%th, coarse sea salt 0.6%, remaining is water；Average mark is loaded on 30 1000mL conical flasks, and 120 DEG C go out 25-30 minutes.
The seed culture fluid that is obtained in appropriate step (1) is taken to access in the conical flask equipped with fermentation medium, in 26~ 28 DEG C of quiescent cultures 24 days.
(3) compound 1-3 extraction separation
According to separation method similar in embodiment 1, compound 1-3, structural identification data and embodiment 1 one can obtain Cause.
Embodiment 4
Take 2.0mg compounds 1 to be dissolved in 2mL methanol, stand spontaneous nucleation, clear crystal (Fig. 1) is obtained after 4 days, it is brilliant Body structure surpasses diffractometer (Xcalibur, Atlas, Gemini ultra diffractometer) with Shuangzi and uses Cu K alpha raysDiffraction data is collected in scanning under 120.01 (10) K.
The crystal of compound 1：Orthorhombic system, space group P212121, cell parameter is α=90 °, β=90 °, γ=90 °,Z=4, Dx= 1.142mg/mm3, F (000)=928, μ (Cu K α)=0.540mm-1, final discrepancy factor R1=0.05046, wR2=0.1067 [I>2 σ (I)], Flack constants are 0.0 (2).
In addition, compound 1 is dissolved in one or more of mixing in ethanol, dichloromethane, petroleum ether or ethyl acetate, it is quiet Above-mentioned crystal can be obtained by putting 3-7 days.
Embodiment 5
Take 1.0mg compounds 1 to be dissolved in 1mL methanol, stand spontaneous nucleation, clear crystal (Fig. 2) is obtained after 5 days, it is brilliant Body structure surpasses diffractometer (Xcalibur, Atlas, Gemini ultra diffractometer) with Shuangzi and uses Cu K alpha raysDiffraction data is collected in scanning under 120.01 (10) K.
The crystal of compound 2：Orthorhombic system, space group P212121, cell parameter is α=90 °, β=90 °, γ=90 °,Z=4, Dx=1.155mg/mm3, F (000)=920, μ (Cu K α)=0.548mm-1, final discrepancy factor R1=0.0323, wR2= 0.0746[I>2 σ (I)], Flack constants are -0.01 (17).
In addition, compound 2 is dissolved in one or more of mixing in ethanol, dichloromethane, petroleum ether or ethyl acetate, it is quiet Above-mentioned crystal can be obtained by putting 3-7 days.
The antitumor activity of embodiment 6 is tested
Using MTT methods to tumour cell A549, Hela, HepG2 carry out cytotoxic activity test, 5-Fu and Adriamycin (adriamycin) is used as positive control drug.
Test result show the crystal of the compounds of this invention 1-3 and compound 1 and 2 to tumour cell A549, Hela, HepG2 shows certain inhibitory activity, IC50For 1-25 μ g/mL, wherein compound 1-2 concrete activity see the table below.

Claims (9)

1. a kind of marine fungi Eupenicillium sp.HJ002, it is characterised in that its culture presevation information is as follows：Preservation list Position title：China Committee for Culture Collection of Microorganisms's common micro-organisms center；Depositary institution address：Chaoyang District, Beijing City north The institute 3 of occasion West Road 1, Institute of Microorganism, Academia Sinica；Preservation date：On December 21st, 2016；Deposit number：CGMCC No.13373；Classification And Nomenclature：Penicillium Eupenicillium sp..
2. a kind of crystal of indoles diterpene-kind compound, it is characterised in that the indoles diterpene-kind compound has following structure：Its X-ray single crystal diffraction data is：Orthorhombic system, space group P212121, cell parameter isα=90 °, β=90 °, γ=90 °,Z=4, Dx=1.142mg/mm3, F (000)=928, μ (Cu K α)=0.540mm-1, finally deviate because Sub- R1=0.05046, wR2=0.1067 [I>2 σ (I)], Flack constants are 0.0 (2).
3. a kind of crystal of indoles diterpene-kind compound, it is characterised in that the indoles diterpene-kind compound has following structure：Its X-ray single crystal diffraction data is：Orthorhombic system, space group P212121, cell parameter isα=90 °, β=90 °, γ=90 °,Z=4, Dx=1.155mg/mm3, F (000)=920, μ (Cu K α)=0.548mm-1, it is final to deviate Factor R1=0.0323, wR2=0.0746 [I>2 σ (I)], Flack constants are -0.01 (17).
4. the preparation method of the crystal described in claim any one of 2-3, comprises the following steps：Compound 1 or 2 is dissolved in solvent In, stand spontaneous nucleation and obtain, the solvent is one kind or several in methanol, ethanol, dichloromethane, petroleum ether or ethyl acetate Kind.
5. a kind of antineoplastic, it is characterised in that active ingredient is used as using the crystal described in claim any one of 2-3.
6. the antineoplastic described in claim 5, it is characterised in that also comprising other antineoplastics.
7. the antineoplastic described in claim any one of 5-6, it is characterised in that also comprising pharmaceutically acceptable carrier or Excipient.
8. purposes of the crystal described in claim any one of 2-3 in antineoplastic is prepared.
9. the purposes described in claim 8, it is characterised in that described tumour preferred A549, Hela, HepG2.
CN201710416276.1A 2017-06-05 2017-06-05 Indole diterpenoid compound crystal and application thereof as antitumor drug Active CN107828663B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710416276.1A CN107828663B (en) 2017-06-05 2017-06-05 Indole diterpenoid compound crystal and application thereof as antitumor drug

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710416276.1A CN107828663B (en) 2017-06-05 2017-06-05 Indole diterpenoid compound crystal and application thereof as antitumor drug

Publications (2)

Publication Number Publication Date
CN107828663A true CN107828663A (en) 2018-03-23
CN107828663B CN107828663B (en) 2021-06-01

Family

ID=61642977

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710416276.1A Active CN107828663B (en) 2017-06-05 2017-06-05 Indole diterpenoid compound crystal and application thereof as antitumor drug

Country Status (1)

Country Link
CN (1) CN107828663B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110483537A (en) * 2019-07-22 2019-11-22 湖南省中医药研究院 Indoles diterpene-kind compound and its screening technique, separation method and application
CN110872338A (en) * 2018-09-04 2020-03-10 中国海洋大学 Indole diterpenoid compound and preparation method and application thereof
CN115490661A (en) * 2022-08-09 2022-12-20 海南师范大学 Antioxidant active compound in mangrove-derived fungi and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006115423A1 (en) * 2005-04-28 2006-11-02 Agresearch Limited Immune response inhibition using indole diterpene compound
CN101445784A (en) * 2008-12-31 2009-06-03 浙江工业大学 Eupenicillium brefeldianum variety ZJB082702 and application thereof in preparation of Brefeldin A by fermentation
CN103274915A (en) * 2013-05-30 2013-09-04 中国人民解放军第二军医大学 Diterpenoid compounds libertellenone G and libertellenone H with antineoplastic activities and application thereof
CN103834703A (en) * 2014-03-03 2014-06-04 天津科技大学 Biosynthesis method of eupenicillium fungus secondary metabolite
CN104817432A (en) * 2015-03-25 2015-08-05 青岛华仁技术孵化器有限公司 Anti-tumor drug of diterpenoid compound, and preparation method and application thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006115423A1 (en) * 2005-04-28 2006-11-02 Agresearch Limited Immune response inhibition using indole diterpene compound
CN101445784A (en) * 2008-12-31 2009-06-03 浙江工业大学 Eupenicillium brefeldianum variety ZJB082702 and application thereof in preparation of Brefeldin A by fermentation
CN103274915A (en) * 2013-05-30 2013-09-04 中国人民解放军第二军医大学 Diterpenoid compounds libertellenone G and libertellenone H with antineoplastic activities and application thereof
CN103834703A (en) * 2014-03-03 2014-06-04 天津科技大学 Biosynthesis method of eupenicillium fungus secondary metabolite
CN104817432A (en) * 2015-03-25 2015-08-05 青岛华仁技术孵化器有限公司 Anti-tumor drug of diterpenoid compound, and preparation method and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SHOU NAKADATE 等: "NEW TYPE INDOLE DITERPENE, EUJINDOLES, FROM EUPENICILLIUM JAVANICUM", 《HETEROCYCLES》 *
杨小岚 等: "23 株海洋真菌的分子鉴定及其抗植物病原真菌和细胞毒活性研究", 《生物技术通报》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110872338A (en) * 2018-09-04 2020-03-10 中国海洋大学 Indole diterpenoid compound and preparation method and application thereof
CN110483537A (en) * 2019-07-22 2019-11-22 湖南省中医药研究院 Indoles diterpene-kind compound and its screening technique, separation method and application
CN115490661A (en) * 2022-08-09 2022-12-20 海南师范大学 Antioxidant active compound in mangrove-derived fungi and preparation method thereof
CN115490661B (en) * 2022-08-09 2023-09-08 海南师范大学 Antioxidant active compound in mangrove-derived fungi and preparation method thereof

Also Published As

Publication number Publication date
CN107828663B (en) 2021-06-01

Similar Documents

Publication Publication Date Title
CN107827805A (en) A kind of indoles diterpene-kind compound of mangrove xylocarpus granatum originated from fungus and preparation method and application
CN102181387B (en) Streptomyces sp. and method for preparing straurosporine and K-252d by utilizing Streptomyces sp.
CN107841466B (en) A method of by marine Penicillum category fungi large scale preparation penicillic acid
CN107828663A (en) A kind of indoles diterpene-kind compound crystal and its application as antineoplastic
CN108753627A (en) A kind of marine aspergillus source oxa- anthraquinone analog compound and preparation method thereof and the application in preparing antitumor agent
CN108660082A (en) A kind of marine aspergillus source oxa- anthraquinone analog compound and preparation method thereof and the application in preparing antiseptic
CN106834160A (en) One class square ring element compound and its application in antitumor or antibacterials are prepared
CN110257255A (en) The chromone derivatives and the preparation method and application thereof in mangrove cusp sea lotus endogenetic fungus source
CN113717866B (en) An endophytic fungus of Hibiscus Adhatoda fruit and its application in preparing antineoplastic active compound
CN106432168B (en) The anti-vibrios reactive compound and preparation method thereof in mangrove cusp sea lotus endogenetic fungus source
CN109486685A (en) A kind of mangrove cusp sea lotus endogenetic fungus and its application in preparation anti-insect activity terpene crystalline compounds
CN109824689A (en) Meroterpenoids compound and the preparation method and application thereof in a kind of mangrove endogenetic fungus
CN109553600A (en) Isocoumarin class compound and the preparation method and application thereof in a kind of mangrove endogenetic fungus
CN110283728A (en) The tetralone derivative and the preparation method and application thereof in mangrove cusp sea lotus endogenetic fungus source
CN103910701A (en) Marine fungus-derived naphthoquinone compound, and preparation method and application thereof
WO2019227969A1 (en) Ansamycin all-carbon cycle polyketide-type antibiotic and uses thereof in preparing antimicrobial medications or anti-tumor medications
CN108727169A (en) A kind of preparation method of the biphenyl ether compound in marine fungi source and the application as antiseptic
CN109942658A (en) A kind of miscellaneous terpene compound and the preparation method and application thereof and anti-tumor drug
CN105399721B (en) Noval chemical compound and preparation method thereof and the application in antibacterial antineoplastic is prepared
CN106432169B (en) A kind of active isocoumarin class compound of anti-vibrios and its crystal
CN114621092A (en) Phenolic compound in mangrove plant-derived fungi and preparation method thereof
CN110642863B (en) 5,5,6 type PTM compound and preparation method and application thereof
CN107226801A (en) A kind of xanthone classes compound and its preparation method of monocrystalline and the application as alpha-glucosidase restrainer
CN107226800A (en) A kind of xanthone classes compound and its preparation method of monocrystalline and the application as anti-Mycobacterium marinum medicine
CN105837590A (en) Compound with anti-Candida albicans activity, preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant